PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.11
D/E ratio near Medical - Pharmaceuticals median of 0.10. Philip Fisher would examine if industry-standard leverage is optimal for the business model.
-0.95
Net cash position versus Medical - Pharmaceuticals median net debt of 0.94. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
No Data
No Data available this quarter, please select a different quarter.
0.70
Current ratio below 50% of Medical - Pharmaceuticals median of 2.12. Michael Burry would check for immediate refinancing needs.
0.09%
Intangibles less than half the Medical - Pharmaceuticals median of 5.18%. Warren Buffett would verify if this conservative approach misses valuable brand-building opportunities.